DE69839682D1 - Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von nicht-Hodgkihn-Lymphome - Google Patents

Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von nicht-Hodgkihn-Lymphome

Info

Publication number
DE69839682D1
DE69839682D1 DE69839682T DE69839682T DE69839682D1 DE 69839682 D1 DE69839682 D1 DE 69839682D1 DE 69839682 T DE69839682 T DE 69839682T DE 69839682 T DE69839682 T DE 69839682T DE 69839682 D1 DE69839682 D1 DE 69839682D1
Authority
DE
Germany
Prior art keywords
hodgki
lymphomas
treatment
arsenic trioxide
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839682T
Other languages
English (en)
Inventor
Ralph M Ellison
Fred H Mermelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PolaRx Biopharmaceuticals Inc
Original Assignee
PolaRx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PolaRx Biopharmaceuticals Inc filed Critical PolaRx Biopharmaceuticals Inc
Application granted granted Critical
Publication of DE69839682D1 publication Critical patent/DE69839682D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69839682T 1997-10-15 1998-10-15 Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von nicht-Hodgkihn-Lymphome Expired - Lifetime DE69839682D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6237597P 1997-10-15 1997-10-15

Publications (1)

Publication Number Publication Date
DE69839682D1 true DE69839682D1 (de) 2008-08-14

Family

ID=22042073

Family Applications (4)

Application Number Title Priority Date Filing Date
DE69840006T Expired - Lifetime DE69840006D1 (de) 1997-10-15 1998-10-15 Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von multiplen Myelom
DE69839682T Expired - Lifetime DE69839682D1 (de) 1997-10-15 1998-10-15 Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von nicht-Hodgkihn-Lymphome
DE69842094T Expired - Lifetime DE69842094D1 (de) 1997-10-15 1998-10-15 Zusammensetzungen und Verfahren zur Behandlung primärer und metastatischer Erkrankungen mithilfe Arsentrioxid
DE69840057T Expired - Lifetime DE69840057D1 (de) 1997-10-15 1998-10-15 Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von Krebs des zentralen Nervensystems

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69840006T Expired - Lifetime DE69840006D1 (de) 1997-10-15 1998-10-15 Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von multiplen Myelom

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69842094T Expired - Lifetime DE69842094D1 (de) 1997-10-15 1998-10-15 Zusammensetzungen und Verfahren zur Behandlung primärer und metastatischer Erkrankungen mithilfe Arsentrioxid
DE69840057T Expired - Lifetime DE69840057D1 (de) 1997-10-15 1998-10-15 Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von Krebs des zentralen Nervensystems

Country Status (21)

Country Link
US (9) US6875451B2 (de)
EP (9) EP1466607A1 (de)
JP (1) JP2001519366A (de)
KR (1) KR20010015755A (de)
CN (1) CN1282218A (de)
AT (4) ATE493979T1 (de)
AU (1) AU751932B2 (de)
BR (1) BR9813085A (de)
CA (1) CA2307208A1 (de)
CY (4) CY1108363T1 (de)
DE (4) DE69840006D1 (de)
DK (4) DK1378240T3 (de)
ES (4) ES2313201T3 (de)
HK (3) HK1061199A1 (de)
IL (1) IL135620A0 (de)
NO (1) NO20001977L (de)
NZ (1) NZ503973A (de)
PL (1) PL339909A1 (de)
PT (4) PT1378240E (de)
TR (1) TR200001959T2 (de)
WO (1) WO1999018798A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399480T3 (es) 1997-11-10 2013-04-01 Memorial Sloan-Kettering Cancer Center Procedimiento de producción de formulaciones de trióxido de arsénico
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
DE10196619D2 (en) * 2001-07-05 2004-05-06 Hans-Werner Luedke Nahrungsergänzungsprodukt oder arzneimittel gegen bestimmte mangelzustände und hirnfunktionsstörungen
AUPR874601A0 (en) 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
KR20030058019A (ko) * 2001-12-29 2003-07-07 한국원자력연구소 삼산화비소(Ａｓ₂Ｏ₃)를 유효 성분으로 포함하는 방사선치료증진제
EP2420229A1 (de) * 2002-01-07 2012-02-22 Board Of Regents, University Of Texas System S-Dimethylarsino-thio-bernsteinsäure, S-Dimethylarsino-thio-benzoesäure, S-(Dimethylarsino)-Glutathion als Behandlungen für Krebs
MXPA04009898A (es) * 2002-04-10 2005-06-20 Korea Microbiological Lab Ltd Composicion farmaceutica que comprende arsenita para el tratamiento de tumores malignos.
US8394422B2 (en) * 2002-04-26 2013-03-12 Centre National De La Recherche Scientifique (Cnrs) Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
KR100492940B1 (ko) * 2002-05-27 2005-06-02 김종배 항종양활성 증진용 조성물
US8906422B2 (en) * 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
US20080089949A1 (en) * 2006-10-13 2008-04-17 Yok-Lam Kwong Method for treating cancer using oral arsenic trioxide
US20080166425A1 (en) * 2002-10-09 2008-07-10 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
CA2504935C (en) 2002-11-07 2012-04-10 Unisearch Limited Induction of the mitochondrial permeability transition
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005062810A2 (en) * 2003-12-18 2005-07-14 Mediscovery, Llc Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide
NZ549731A (en) * 2004-03-01 2009-11-27 Peptimmune Inc Methods and compositions for treatment of autoimmune diseases
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm
US20050208149A1 (en) * 2004-03-18 2005-09-22 Tty Biopharm Limited Company Use of arsenic-containing pharmaceutical composition in combination with radiation therapy for cancer treatment
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
WO2006002082A2 (en) 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
TW201350113A (zh) * 2004-07-16 2013-12-16 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
US20070292478A1 (en) * 2004-08-30 2007-12-20 Popowski Youri Medical Implant Provided with Inhibitors of Atp Synthesis
WO2006102439A2 (en) * 2005-03-23 2006-09-28 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
EP1721615A1 (de) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmazeutische Zusammensetzung enthaltend Natrium- oder Kaliumarsenit zur Behandlung von Urogenitalkrebs und seinen Metastasen
WO2007027344A2 (en) 2005-07-29 2007-03-08 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
US8246983B2 (en) * 2005-09-02 2012-08-21 Northwestern University Encapsulated arsenic drugs
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
US8784899B2 (en) * 2005-10-04 2014-07-22 Samuel Waxman Cancer Research Foundation Compositions and methods for cancer treatment
US20080233207A1 (en) * 2006-01-04 2008-09-25 Sheptovitsky Yelena G Injectable and Infusable Mercury Compositions and Methods for Treating Cancer
ITMI20060480A1 (it) * 2006-03-16 2007-09-17 Solvay Solexis Spa Usom di perfluoropolimeri nella dtermibnazione della costante di legame recettore-ligando
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
US20080089951A1 (en) * 2006-10-11 2008-04-17 The University Of Hong Kong Method for Inhibiting Cancer Using Arsenic Trioxide
WO2008052279A1 (en) 2006-11-01 2008-05-08 Newsouth Innovations Pty Limited Organo-arsenoxide compounds and use thereof
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
CN101662939B (zh) 2007-02-06 2015-11-25 利克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途
CA2718472A1 (en) * 2007-08-03 2009-02-12 Lixte Biotechnology, Inc. Use of phosphatases to treat neuroblastomas and medulloblastomas
EP2200439B1 (de) 2007-10-01 2017-03-22 Lixte Biotechnology, Inc. Hdac-hemmer
AU2008325243B2 (en) * 2007-11-02 2014-07-03 Solasia Pharma K.K. Combination therapy with organic arsenicals
CN101874034A (zh) * 2007-12-12 2010-10-27 Zio医药肿瘤学公司 用于治疗癌症的化合物和方法
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
AU2009277086B2 (en) * 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
CA2730428A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US8227473B2 (en) * 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
BRPI0918407A2 (pt) 2008-08-20 2015-11-24 Ziopharm Oncology Inc compostos organoarsênicos e métodos para o tratamento de câncer
KR101100786B1 (ko) * 2008-12-16 2011-12-29 (주)천지산 암에 대한 방사선 치료 증진용 조성물
RU2568834C2 (ru) * 2009-09-10 2015-11-20 Коминокс, Инк. Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
KR20120048706A (ko) * 2009-09-18 2012-05-15 코미녹스 인코포레이티드 뇌종양 치료 방법
US20120015023A1 (en) * 2010-04-15 2012-01-19 Antimisiaris Sophia G Treatment of tumors prostate with arsonoliposomes
WO2014152330A1 (en) * 2013-03-15 2014-09-25 Stc.Unm Arsenic-based treatment of cancers and inflammatory disorders
US20160015743A1 (en) * 2013-03-15 2016-01-21 Rush University Medical Center Methods for treating cancer
EP2983661B1 (de) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulierungen von oxabicycloheptanen und oxabicycloheptenen
FR3004949B1 (fr) * 2013-04-26 2016-02-05 Centre Nat Rech Scient Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale
US9700580B1 (en) 2016-06-14 2017-07-11 Marguerite Harning Method for cancer treatment
NZ752214A (en) 2016-12-01 2022-11-25 Eupharma Pty Ltd Arsenic compositions
KR101844050B1 (ko) 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
WO2018209343A1 (en) * 2017-05-12 2018-11-15 Rajur Sharanappa Basappa Novel methods, compounds, and compositions: small molecule anticancer agents
WO2019234112A1 (en) 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
CN112675197A (zh) * 2021-01-22 2021-04-20 中山大学孙逸仙纪念医院 一种用于儿童Hedgehog信号通路驱动肿瘤的药物组合物
CN114028425A (zh) * 2021-09-24 2022-02-11 上海交通大学医学院附属新华医院 硫化砷及其与放疗联合在治疗横纹肌肉瘤上的应用
CN115634287A (zh) * 2022-09-30 2023-01-24 苏州系统医学研究所 一种基于砷化合物的肿瘤疫苗及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US232807A (en) 1880-10-05 Herbert e
US132275A (en) 1872-10-15 Improvement in medical compounds
US3700498A (en) 1970-12-10 1972-10-24 Ibm Process for making electrophotographic plates
JPS5188620A (en) 1975-01-31 1976-08-03 Jintainokenkonoiji kotonigannitaishitekonoojusuru noshukuionekinoseizoho
DE3003635C2 (de) 1980-02-01 1985-07-11 Klöckner-Humboldt-Deutz AG, 5000 Köln Verfahren und Vorrichtung zur Entarsenierung arsenhaltiger Materialien
US4599305A (en) * 1984-07-16 1986-07-08 The Regents Of The University Of California Method and composition for detection of human chronic myelogenous leukemia
NL8502929A (nl) * 1985-10-25 1987-05-18 Tno Groep viii-overgangsmetaal-complexen, werkwijze voor het bereiden daarvan, werkwijze voor het bereiden van een geneesmiddel met toepassing van een dergelijke groep viii-overgangsmetaal-complex voor de behandeling van kanker, alsmede aldus verkregen gevormd geneesmiddel.
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
CN1061908A (zh) 1991-12-21 1992-06-17 江西省妇产医院 一种治癌药物的制造方法
CN1060935C (zh) 1992-05-31 2001-01-24 丛繁滋 用于癌病灶直接给药的砷制剂的制备方法
CN1044777C (zh) 1992-07-06 1999-08-25 杨世泽 癌痛止痛膏的配制方法
MX9304501A (es) 1992-07-24 1994-04-29 Univ Johns Hopkins Quimioterapia para cancer.
FR2699820B3 (fr) * 1992-12-24 1995-03-10 Eric Pichot Traitement homéopathique préventif des dysmytoses (cancer, leucémie) et malformations ou mutations génétiques.
DE4317331A1 (de) * 1993-05-25 1994-12-01 Reischle Karl Georg Behandlung von Schädigungen des Immunsystems
ITTO930510A1 (it) 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
EP0804928B1 (de) 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
CN1119113A (zh) 1994-09-22 1996-03-27 衣永德 复方癌复康胶囊及制备方法
CN1122700A (zh) 1994-11-08 1996-05-22 付知中 一种治疗乳腺疾病、肿瘤疮毒的散剂及其制备方法
LV11667B (en) * 1995-08-14 1997-06-20 Tamara Vorobieva Remedy for renewal of disordered function of immunomodulation and cell tissue reproduction adjustors
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
CN1202809A (zh) * 1995-10-06 1998-12-23 光电子有限公司 将x射线作用到一个体腔的内表面的改进型装置
CN1058620C (zh) 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
CN1052648C (zh) 1995-12-03 2000-05-24 唐书生 癌瘤消肿止痛膏
ES2399480T3 (es) 1997-11-10 2013-04-01 Memorial Sloan-Kettering Cancer Center Procedimiento de producción de formulaciones de trióxido de arsénico
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
BR0314647A (pt) * 2002-09-24 2005-08-02 Novartis Ag Uso de derivados de 4-piridilmetil-ftalazina para a preparação de um medicamento para o tratamento de sìndromes melodisplásicas
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm

Also Published As

Publication number Publication date
WO1999018798A1 (en) 1999-04-22
US7205001B2 (en) 2007-04-17
IL135620A0 (en) 2001-05-20
DK1621077T3 (da) 2009-01-26
DE69840057D1 (de) 2008-11-06
ES2313201T3 (es) 2009-03-01
US7163703B2 (en) 2007-01-16
US20050191367A1 (en) 2005-09-01
AU1089399A (en) 1999-05-03
CA2307208A1 (en) 1999-04-22
EP1022951A4 (de) 2002-06-19
EP2018858A1 (de) 2009-01-28
EP1378241A1 (de) 2004-01-07
US20040161475A1 (en) 2004-08-19
US20040096518A1 (en) 2004-05-20
US20040047916A1 (en) 2004-03-11
TR200001959T2 (tr) 2000-11-21
EP2018858B1 (de) 2011-01-05
DE69840006D1 (de) 2008-10-23
ES2312701T3 (es) 2009-03-01
US20040197420A1 (en) 2004-10-07
PT1621077E (pt) 2008-11-04
EP1374875A2 (de) 2004-01-02
CY1111379T1 (el) 2015-08-05
EP1419778A1 (de) 2004-05-19
EP1378240A3 (de) 2004-01-14
ATE409043T1 (de) 2008-10-15
CY1110057T1 (el) 2015-01-14
HK1085886A1 (en) 2006-09-08
DK2018858T3 (da) 2013-01-07
CN1282218A (zh) 2001-01-31
ATE407683T1 (de) 2008-09-15
BR9813085A (pt) 2000-08-22
US20020183385A1 (en) 2002-12-05
US7179493B2 (en) 2007-02-20
US20040197421A1 (en) 2004-10-07
NO20001977D0 (no) 2000-04-14
HK1061198A1 (en) 2004-09-10
DK1378240T3 (da) 2008-12-08
NZ503973A (en) 2001-09-28
PT1378240E (pt) 2008-11-14
EP1022951A1 (de) 2000-08-02
EP1466607A1 (de) 2004-10-13
EP1378240A2 (de) 2004-01-07
PT1391206E (pt) 2008-08-13
NO20001977L (no) 2000-06-13
ATE493979T1 (de) 2011-01-15
CY1108363T1 (el) 2014-02-12
US20050100611A1 (en) 2005-05-12
EP1391206A1 (de) 2004-02-25
PT2018858E (pt) 2011-03-24
CY1110055T1 (el) 2015-01-14
PL339909A1 (en) 2001-01-15
EP1621077B1 (de) 2008-09-24
ES2309258T3 (es) 2008-12-16
EP1378240B1 (de) 2008-09-10
US6875451B2 (en) 2005-04-05
ES2358624T3 (es) 2011-05-12
US20040115283A1 (en) 2004-06-17
JP2001519366A (ja) 2001-10-23
EP1621077A1 (de) 2006-02-01
EP1374875A3 (de) 2004-01-07
DK1391206T3 (da) 2008-09-01
ATE399560T1 (de) 2008-07-15
AU751932B2 (en) 2002-08-29
DE69842094D1 (de) 2011-02-17
KR20010015755A (ko) 2001-02-26
US7132116B2 (en) 2006-11-07
EP1391206B1 (de) 2008-07-02
HK1061199A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
DE69839682D1 (de) Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von nicht-Hodgkihn-Lymphome
IL150767A (en) Benzophyrene compounds and their use in the manufacture of drugs for the treatment of estrogen-sensitive diseases such as endometrial cancer
ATE294595T1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
DE3689363D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung der Metastasen von Krebstumoren.
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
ATE64531T1 (de) Tumortherapeutikum und verfahren zu seiner herstellung.
BR0012921A (pt) Compostos calcilìticos
ATE159171T1 (de) Arzneimittelzusammensetzung enthaltend tcf-ii
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
ATE306255T1 (de) 19-nor-vitamin d3 derivate mit calciumspiegel erhöhender wirkung
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
ATE512664T1 (de) Sphingomyelin enthaltende zusammensetzung zur behandlung der rheumatoiden arthritis
ATE338541T1 (de) Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien
MX9709683A (es) Uso de derivados de vitamina d4 para tratamiento contra el cancer.
DE69819875D1 (de) Anhydrovinblastin zur behandlung von krebs
ATE49965T1 (de) Verwendung von 2-beta-d-ribofuranosylthiazol-4carboxamiden zur herstellung von medikamenten zur behandlung von krebsartigen tumoren.
MX9800129A (es) 2-aminocarbonil-1, 2-bis(metilsulfonil)-1-(substituidas) hidracinas antitumorales.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition